CELLemedy Overview
- Year Founded
-
2016

- Status
-
Private
- Employees
-
7

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$8.93M
- Investors
-
6
CELLemedy General Information
Description
Developer of cancer immunotherapy designed to provide a cure through smart nano-medicine. The company offers cancer cell-related therapeutics, and immuno-oncology drugs through research and development, enabling doctors to improve the health of patients suffering from cancer.
Contact Information
Website
www.cellemedy.comCorporate Office
- Room 4301, Healthcare Innovation Park
- 172 Dolma-ro, Bundang-gu
- Seongnam, Gyeonggi
- South Korea
Corporate Office
- Room 4301, Healthcare Innovation Park
- 172 Dolma-ro, Bundang-gu
- Seongnam, Gyeonggi
- South Korea
CELLemedy Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC (Series A) | 20-Sep-2023 | $8.93M | Completed | Pre-Clinical Trials | ||
1. Seed Round | 01-Dec-2020 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
CELLemedy Patents
CELLemedy Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240374744-A1 | Protein and pharmaceutical composition comprising same for prevention or treatment of cancer | Pending | 17-Sep-2021 | ||
EP-4403567-A1 | Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer | Pending | 17-Sep-2021 | ||
CA-3232442-A1 | Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer | Pending | 17-Sep-2021 | ||
AU-2022346534-A1 | Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer | Pending | 17-Sep-2021 | ||
EP-4335450-A1 | Pharmaceutical composition for prevention or treatment of lung cancer | Pending | 03-May-2021 | A61K38/1709 |
CELLemedy Signals
CELLemedy Investors (6)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
CKD Venture Capital | Corporate Venture Capital | Minority | ||
IBC Capital (Seoul) | Venture Capital | Minority | ||
Stonebridge Ventures (Seoul) | Corporate Venture Capital | Minority | ||
DAYLI Partners | Venture Capital | Minority | ||
IMM Investment | Asset Manager | Minority |
CELLemedy FAQs
-
When was CELLemedy founded?
CELLemedy was founded in 2016.
-
Where is CELLemedy headquartered?
CELLemedy is headquartered in Seongnam, South Korea.
-
What is the size of CELLemedy?
CELLemedy has 7 total employees.
-
What industry is CELLemedy in?
CELLemedy’s primary industry is Biotechnology.
-
Is CELLemedy a private or public company?
CELLemedy is a Private company.
-
What is CELLemedy’s current revenue?
The current revenue for CELLemedy is
. -
How much funding has CELLemedy raised over time?
CELLemedy has raised $12.5M.
-
Who are CELLemedy’s investors?
CKD Venture Capital, IBC Capital (Seoul), Stonebridge Ventures (Seoul), DAYLI Partners, and IMM Investment are 5 of 6 investors who have invested in CELLemedy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »